Connect with us

Technology

Diaceutics announces “Precision Medicine in Oncology ” Virtual Event: A Cutting-Edge Exploration of Cancer Diagnostics & Treatment

Published

on

Diaceutics PLC (AIM: DXRX), a leading technology & solutions provider to the pharma & biotech industry, is pleased to announce its upcoming virtual event. “Precision medicine in oncology,” on 19 June, 2024.

BELFAST, Northern Ireland and LONDON, June 10, 2024 /PRNewswire-PRWeb/ — Diaceutics PLC (AIM: DXRX), a leading technology & solutions provider to the pharma & biotech industry, is pleased to announce its upcoming virtual event. “Precision medicine in oncology,” on 19 June, 2024.

This groundbreaking event will take attendees to the forefront of cancer testing & treatment through a series of eight live webinars, culminating in a full day of immersive, true-to-life virtual experiences.

This groundbreaking event will take attendees to the forefront of cancer testing & treatment through a series of eight live webinars, culminating in a full day of immersive, true-to-life virtual experiences. The sessions will cover cutting-edge topics that are revolutionising cancer analysis & diagnostics, including immunotherapy, liquid biopsy, pre-analytical phase, NGS, cytology, & CE-IVDR. Participants will gain firsthand insights from top laboratory experts, enhancing their understanding of these critical advancements.

Event Speakers will include:

Prof. Dr. Klaus Pantel, Director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf, Germany: Presenting “Implementation of Liquid Biopsy in Precision Oncology,” Dr Pantel, a pioneer in cancer cell research, will provide a comprehensive introduction & review to the evolution of precision medicine, focusing on the implementation of liquid biopsy in precision oncology.Dr. Bob Holt, Senior Precision Medicine Strategy Advisor at Diaceutics: Presenting “MRD in Solid Tumor & Hematological Indications: Today & Tomorrow,” Dr Holt will analyse the clinical utility & technology behind Minimal Residual Disease (MRD). This session will be followed by Prof. Maria Teresa Voso, Prof. of Hematology at Tor Vergata University, who will discuss the pros & cons of of MRD in AML & engage in a discussion with Dr. Holt & all attendees.Prof. Paul Hoffman, Professor of Pathology at the University Côte d’Azur, Nice France: Presenting on “New challenges in early-stage cancer”. This presentation will explore early detection & management of early-stage cancers.Dr. Clare Turnbull PhD FRCP FRCPath FFPH, Professor of Translational Cancer Genetics in the Division of Genetics & Epidemiology at the Institute of Cancer Research NHS Honorary Consultant in Clinical Cancer Genetics, London & Dr. Nicola Normanno, MD, Director of Translational Research, National Cancer Institute, Italy Pascale Foundation, Italy: Presenting “The Role of Comprehensive Genomic Profiling in Precision Oncology,” this session promises insights into the implications of large NGS panels, co-mutations, & the introduction of patients harboring germline variants.Prof. Sophie Prévot, Pathologist at the Bicêtre Hospital, Paris: Presenting “Integrating AI in Pathology: Advancing Diagnoses & Workflow Efficiency,” this presentation will explore how AI tools can support doctors in making accurate diagnoses & enhancing workflow efficiency.

Ryan Keeling, CEO of Diaceutics, commented, “Our commitment is to challenge the landscape of cancer treatment through precision medicine. This event provides an unparalleled platform for experts to share innovative practices & insights that will shape the future of oncology diagnostics. We are excited to host this gathering of thought leaders & advance our mission of ensuring every patient receives the right treatment at the right time.”

The event is tailored for laboratory professionals, pathologists, & anyone involved in oncology diagnostics & treatment. In addition to the expert presentations, attendees can participate in interactive sessions, visit the poster hall, & engage in real-time Q&A sessions with expert speakers.

For further information about the event & to register for free, click here.

About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test & the right therapy to positively impact their disease outcome.

We provide the world’s leading pharma & biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific & advisory services enabled by our platform DXRX – The Diagnostics Network®

About Labroots
Labroots is the leading scientific social networking website, & primary source for scientific trending news & premier educational virtual events & webinars & more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks & communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration & learning. Offering more than articles & webcasts that go beyond the mundane & explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars & virtual events.

Media Contact

Akshay Masand, Labroots, + 1.714.463.4673, akshay.masand@labroots.com, https://www.labroots.com/

View original content to download multimedia:https://www.prweb.com/releases/diaceutics-announces-precision-medicine-in-oncology–virtual-event-a-cutting-edge-exploration-of-cancer-diagnostics–treatment-302168464.html

SOURCE Labroots

Continue Reading

Technology

SK hynix Announces 3Q26 Financial Results

Published

on

By

Reports revenues of 104.6155 trillion won, operating profit of 83.3338 trillion won, net profit of 39.7756 trillion won; Quarterly sales surpass 100 trillion won for the first timeSales of HBM4 and high-value-added server products expanded; HBM4 expected to be the mainstream product from the fourth quarterLong-term agreements secured for more than 50% of 2027~2028 production capacity; A structure that reflects market conditions and ensures stable profitabilityMost of the gains from the Kioxia investment to be shared with shareholders, with  approximately 100 trillion won in shareholder returns to be executed this year

SEOUL, South Korea, Oct. 27, 2026 /PRNewswire/ — SK hynix Inc. (or “the company”, www.skhynix.com) announced today that it has recorded 104.6155 trillion won in revenues, 83.3338 trillion won in operating profit (with an operating margin of 80%), and 39.7756 trillion won in net profit (with a net margin of 38%) in the third quarter.

Record quarterly results in both revenue and operating profit and revenue surpasses 100 trillion won for the first time

In a market environment in which prices of key products have risen on the back of growing demand for AI memory, the company once again posted all-time-high quarterly results in both revenue and operating profit, underpinned by the competitiveness of its high-value-added products. In particular, revenue exceeded 100 trillion won for the first time in the company’s history. Revenue and operating profit increased by 32% and 38%, from the previous quarter, respectively.

– Q2 2026: Revenue of 79.3187 trillion won, Operating Profit of 60.5426 trillion won

By product, DRAM results were driven by a significant increase in sales of server DDR5 while HBM4 shipments began in earnest. In NAND, sales of 321-layer TLC eSSD expanded, and high-value-added products for data centers continued to grow across the board.

The company’s financial structure has also become significantly concrete. At the end of the third quarter, cash and cash equivalents stood at 114.5 trillion won, up 26.5 trillion won from the end of the previous quarter, while borrowings decreased by 2.8 trillion won to 15.8 trillion won. As a result, net cash increased to 98.7 trillion won.

Memory supply shortage to persist through 2030

SK hynix analyzed that a virtuous cycle has taken hold in which AI-driven productivity gains and new revenue generation in areas such as software development, customer service, and search lead to greater AI adoption, which in turn drives increased investment in infrastructure. It also projected that, as the drivers of AI investment move beyond the early stage, when a small number of companies accounted for most of it, and broaden to include general enterprises and nation-level initiatives, the global AI data center infrastructure market will continue to grow steadily.

The company likewise expects the memory market to sustain its growth, led in the short term by enterprise and personal AI and, over the mid-to-long term, by physical AI such as autonomous driving and robotics.

The company assessed that supply, on the other hand, is not keeping pace with the growth of the market. Given technical difficulty of leading-edge processes and the long lead time required to build new production facilities, it expects the structure in which demand exceeds supply to persist through 2030.

Expanding production capacity and strengthening product competitiveness to achieve a further step up in growth next year

Building on these favorable conditions, the company plans to accelerate the expansion of production capacity and the strengthening of product competitiveness in order to sustain the current growth momentum, and to scale up revenue and profit one step further next year.

First, the company plans to rapidly increase the portion of its 10nm-class 6th generation (1c) process technology and expand sales of DDR5 and LPDDR5 SOCAMM for AI servers, thereby further strengthening its DRAM portfolio centered on high-value-added products.

To respond to surging HBM demand, the company will ramp up M15X to maximum capacity by the end of the year to increase HBM4 production. Accordingly, the company expects HBM4 to surpass HBM3E in both shipment volume and revenue in the fourth quarter and to establish itself as a mainstream product.

In NAND, the company will raise the ratio of its 321-layer process to more than half of its domestic production capacity in the fourth quarter, and thereby increase the supply of high-performance, high-capacity eSSD. Over the mid-to-long term, the company intends to develop NAND into a core solution that enhances the throughput and economic efficiency of AI services, based on HBF and system optimization technologies.

Long-term agreements secured for more than 50% of 2027~2028 production capacity and the company to drastically expand investment next year

To improve mid-to-long term demand visibility and solidify its growth foundation, SK hynix is expanding long-term agreements (LTAs) with customers. The company has currently signed LTAs with 14 major customers, including leading global cloud service providers (CSPs), and is also proactively discussing with a number of customers the possibility of extending the contract terms, which are typically five years.

The LTA volume secured to date corresponds to more than 50% of total production capacity for 2027 and 2028. In particular, by introducing a mechanism that reflects market conditions within a price range agreed upon with customers, the company has established a structure that secures stable profitability while allowing flexible responses to market changes.

Backed by the demand visibility, the company is also moving to expand its production capabilities. Next year, with the Yongin Phase 1 entering full-scale operation and domestic and overseas infrastructure investment gaining momentum, investment is expected to increase significantly. The company nevertheless plans to adjust the scale and timing of its investment flexibly, after carefully weighing customer demand, product competitiveness, profitability and investment efficiency.

Most of the gains from the Kioxia investment to be shared with shareholders, with approximately 100 trillion won in shareholder returns to be executed this year

As previously indicated in August, SK hynix announced its additional shareholder return plan. For fiscal year 2026, the company will pursue shareholder returns totaling approximately 100 trillion won, comprising cash dividends of 30 trillion won or more and share repurchases and cancellations of 60 trillion won or more in total, including the 40 trillion won announced in August. Through this, the company intends to fulfill its commitment to return 50% or more of free cash flow (FCF). Of this, the 40 trillion won share repurchase announced in August was completed last week, and the shares will be cancelled shortly.

The company also set out its principles: the dividend amount will be determined on the basis of operating results; if significant investment gains arise, they will be returned additionally through special dividends; and share repurchases will continue every quarter.

At today’s meeting, the Board of Directors resolved on a third-quarter cash dividend of 14 trillion won and a share repurchase of 20 trillion won. Of the shares to be repurchased, 10 trillion won, earmarked for shareholder returns, will be cancelled in full, while the remaining approximately 10 trillion won will be used for employee compensation and is not included in the shareholder return total.

The third-quarter dividend is 20,000 won per share, consisting of a 10,000-won dividend reflecting improved earnings and a 10,000 won special dividend that shares the gains from the Kioxia investment. The company has decided to return to shareholders most of the gains realized from its Kioxia investment this year.

SK hynix emphasized that it will deliver stable results based on robust memory demand growth and technological competitiveness and the company will consistently share financial achievements with our shareholders.

 3Q26 Financial Results (K-IFRS)

*Unit: Billion KRW

3Q26

QoQ

YoY

2Q26

Change

3Q25

Change

Revenues

104,615.5

79,318.7

32 %

24,448.9

328 %

Operating Profit

83,333.8

60,542.6

38 %

11,383.4

632 %

Operating Margin

80 %

76 %

3%p

47 %

33%p

Net Income

39,775.6

93,922.6

-58 %

12,597.5

216 %

* Financial information of the earnings is based on K-IFRS

* Please note that the financial results discussed herein are preliminary and speak only as of October 28, 2026. Readers should not assume that this information remains operative at a later time.

* Percentage changes are calculated on the basis of unrounded figures.

Disclaimer

This material has been prepared by the Company for informational purposes only, and the information contained herein has not undergone any separate, independent verification process. No representations or warranties are made regarding the fairness, accuracy, or completeness of the information contained in this material, and such information should not be relied upon. Neither the Company nor its employees bear any civil, criminal, or administrative liability for any damages arising from this material or from its use.

Review of the FY2026 Q3 financial results has not been finalized. Figures in this earnings release are subject to changes during the independent auditing process.

All financial information contained in this document is based on consolidated K-IFRS.

This material contains forward-looking statements, which involve risks and uncertainties. These statements are generally identified words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” and similar expressions, or the negative of such expressions. Forward-looking statements are not guarantees of future performance and are subject to inherent risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. SK hynix undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

This material does not constitute a solicitation for the acquisition or purchase of securities, and no part of this material should serve as the basis for any contract, agreement, or investment decision, nor should it be relied upon in connection therewith.

About SK hynix Inc.

SK hynix Inc., headquartered in Korea, is the world’s top tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

View original content:https://www.prnewswire.com/news-releases/sk-hynix-announces-3q26-financial-results-302921407.html

SOURCE SK hynix Inc.

Continue Reading

Technology

DealLabs Builds Travel AI Data Layer with 280,000 Verified Local Records Across Seven Asian Cities

Published

on

By

SEOUL, South Korea, Oct. 28, 2026 /PRNewswire/ — Seoul-based travel data company DealLabs announced that it has built a database of verified local travel information for seven Asian cities: Seoul, Busan, Tokyo, Osaka, Bangkok, Taipei, and Singapore. As of October 13, the database contained more than 280,000 records, each accompanied by its source and verification date. It powers more than 23,000 guide pages and is published in formats AI systems can read directly.

It covers what travelers look for after arriving: subway station exits, timetables, first and last trains, fares, restaurants, tourist attractions, hospitals, closing days for Singapore’s hawker centers, and business hours for Taipei’s night markets. In Osaka alone, the database contains more than 114,000 records, including more than 42,000 medical institutions and pharmacies and more than 30,000 restaurant permits. In Taipei, it contains more than 63,000 records, including 7,200 station-to-station fares.

The number of times generative AI search and answer services accessed DealLabs’ data increased from around 600 times per day on a seven-day average in late September to more than 11,000 times per day in mid-October, nearly 20-fold in less than a month.

Travel information changes rapidly. On the same day, public event listings and organizers’ own notices gave different end dates for three of 25 pop-up stores in Seoul, up to 10 days apart. Business hours, closing days, last train times, and fares are among the areas where AI travel answers are most frequently inaccurate. DealLabs continuously updates this information using official sources.

All seven cities have AI-ready guide files (llms.txt) and data APIs, while Seoul also provides a standard API specification (OpenAPI). The seven cities are run using a single common engine, allowing a new city to be added simply by incorporating that city’s data and sources.

DealLabs is also piloting “Visit Plan Check,” which checks travel AI itineraries against official sources daily.

Young Cho, founder and CEO of DealLabs, said, “When travelers ask AI a question, what matters is whether the answer is accurate for that city today. We will establish a standard for local data that travel AI can rely on.”

DealLabs plans to expand its coverage to 10 cities by the end of 2026 and to 30 cities, including New York and Paris, by 2028.

For more information, please visit https://deallabs.net.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/deallabs-builds-travel-ai-data-layer-with-280-000-verified-local-records-across-seven-asian-cities-302920425.html

SOURCE DEALLABS

Continue Reading

Technology

Teijin Selects Kharon to Strengthen Export Controls Compliance Across Global Operations

Published

on

By

Kharon ClearView will support Teijin teams in Japan, the United States, and Europe as they navigate Japanese and U.S. export controls requirements.

DENVER, Oct. 28, 2026 /PRNewswire/ — Kharon, a data and technology company that provides risk intelligence solutions to help organizations manage regulatory and business risk, announced that Teijin Limited has selected Kharon ClearView to support its export controls compliance program.

Headquartered in Japan, Teijin operates a global materials business that includes carbon fiber and other advanced materials used in aerospace and industrial applications. Its international operations require compliance teams to navigate export control requirements across multiple jurisdictions, including Japan and the United States.

“As a global company, we need an export controls approach that can support our teams across markets,” said Hitoshi Onodera, General Manager of the Quality Assurance and Security Export Control Department and Manager of the Security Export Control Group at Teijin. “We selected Kharon because of the depth of its risk intelligence, ease of use, and its ability to give our teams greater visibility into the entities and relationships that matter to our reviews. ClearView will help us bring that context consistently into our due diligence processes across our operations.”

Teijin will deploy ClearView across its operations globally. ClearView enables compliance teams to investigate complex entity relationships, including ownership and commercial connections to parties subject to export controls and other trade restrictions.

“Advanced materials companies operate in an increasingly complex export controls environment, where understanding the parties behind a transaction can be just as important as screening the names directly involved,” said Ethan Woolley, Global Director of Strategy at Kharon. “Teijin’s decision to deploy ClearView across its operations reflects the importance of having that level of insight. We are pleased to support its teams as they strengthen their approach to export controls compliance.”

About Teijin

Teijin Limited is a Japan-based global technology company providing products and solutions across advanced materials, healthcare, and other technology-driven fields. Founded in 1918, Teijin’s businesses include high-performance materials such as aramid fibers, carbon fibers, and composites, serving applications across mobility, infrastructure, industry, and other markets. The Teijin Group comprises 126 companies and approximately 15,700 employees worldwide.

For more information, visit https://www.teijin.co.jp/.

About Kharon

Kharon’s intelligence supports compliance, trade, risk, and national security programs at organizations around the world, including seven of the 10 largest U.S. banks, six of the 10 largest EU banks, and over 35 Fortune 100 companies. Kharon’s data can also be directly integrated with AI applications and agentic operations through Kharon’s API, MCP, and agent gateway infrastructure, enabling organizations to embed Kharon’s sourced, structured insights into automated workflows alongside their teams.

Visit kharon.com and follow Kharon on LinkedIn to stay connected.

Media contact

Kharon
media@kharon.com

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/teijin-selects-kharon-to-strengthen-export-controls-compliance-across-global-operations-302921369.html

SOURCE Kharon

Continue Reading

Trending